WNT5A is a Putative Epi-driver of Prostate Cancer Metastasis to the Bone

Overview

Journal Cancer Med

Specialty Oncology

Date 2024 Aug 21

PMID 39164966

Authors

Emma J Wilkinson

Kelsie Raspin

Roslyn C Malley

Shaun Donovan

Louise M Nott

Adele F Holloway

Joanne L Dickinson

Affiliations

Soon will be listed here.

Abstract

Background: Current diagnostic tools are unable to distinguish low-grade indolent prostate cancer (PrCa) from that with a propensity to become metastatic and/or lethal. Recent evidence suggests that reprogramming of the transcriptome may drive the metastatic phenotype, and that this reprogramming is controlled, at least in part, by epigenetic changes to the DNA of cancer cells, including methylation. These changes, referred to as 'epigenetic drivers,' have previously been associated with cancer cell survival.

Methods: Here, using Illumina Methylation EPIC array data of paired primary PrCa and metastatic bone samples, we identified WNT5A as a putative epi-driver of PrCa metastasis to the bone, which was further validated in vitro.

Results: Significantly higher WNT5A methylation was observed in primary PrCa samples and 22Rv1 cells compared to metastatic bone samples and PC-3 cells. This higher methylation was associated with significantly lower WNT5A gene expression.

Conclusion: Given the limited effective therapies available for metastatic cancer sufferers, particularly those whose disease has metastasised to the bone, WNT5A presents as a potential putative target for therapy.

Citing Articles

Prostate Cancer Bone Metastasis: Molecular Mechanisms of Tumor and Bone Microenvironment.

Jiang H Cancer Manag Res. 2025; 17:219-237.

PMID: 39912095 PMC: 11796448. DOI: 10.2147/CMAR.S495169.

WNT5A is a putative epi-driver of prostate cancer metastasis to the bone.

Wilkinson E, Raspin K, Malley R, Donovan S, Nott L, Holloway A Cancer Med. 2024; 13(16):e70122.

PMID: 39164966 PMC: 11335815. DOI: 10.1002/cam4.70122.

References

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J . Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene. 2007; 26(45):6560-5. DOI: 10.1038/sj.onc.1210472. View

Norgaard M, Jensen A, Jacobsen J, Cetin K, Fryzek J, Sorensen H . Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010; 184(1):162-7. DOI: 10.1016/j.juro.2010.03.034. View

Gujral T, Chan M, Peshkin L, Sorger P, Kirschner M, MacBeath G . A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell. 2014; 159(4):844-56. PMC: 4243058. DOI: 10.1016/j.cell.2014.10.032. View

Jin F, Qu X, Fan Q, Wang L, Tang T, Hao Y . Regulation of prostate cancer cell migration toward bone marrow stromal cell-conditioned medium by Wnt5a signaling. Mol Med Rep. 2013; 8(5):1486-92. DOI: 10.3892/mmr.2013.1698. View

Zhou W, Mei J, Gu D, Xu J, Wang R, Wang H . Wnt5a: A promising therapeutic target in ovarian cancer. Pathol Res Pract. 2021; 219:153348. DOI: 10.1016/j.prp.2021.153348. View

Dai J, Hall C, Escara-Wilke J, Mizokami A, Keller J, Keller E . Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res. 2008; 68(14):5785-94. PMC: 4432935. DOI: 10.1158/0008-5472.CAN-07-6541. View

Zheng G, Ma Y, Zou Y, Yin A, Li W, Dong D . HCMDB: the human cancer metastasis database. Nucleic Acids Res. 2017; 46(D1):D950-D955. PMC: 5753185. DOI: 10.1093/nar/gkx1008. View

Ayres Pereira M, Chio I . Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies. Genes (Basel). 2019; 11(1). PMC: 7016631. DOI: 10.3390/genes11010006. View

10.

Cavalcante R, Sartor M . annotatr: genomic regions in context. Bioinformatics. 2017; 33(15):2381-2383. PMC: 5860117. DOI: 10.1093/bioinformatics/btx183. View

11.

Rycaj K, Tang D . Molecular determinants of prostate cancer metastasis. Oncotarget. 2017; 8(50):88211-88231. PMC: 5675705. DOI: 10.18632/oncotarget.21085. View

12.

Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View

13.

Li J, Ying J, Fan Y, Wu L, Ying Y, Chan A . WNT5A antagonizes WNT/β-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma. Cancer Biol Ther. 2010; 10(6):617-24. DOI: 10.4161/cbt.10.6.12609. View

14.

Krainer J, Weinhausel A, Hanak K, Pulverer W, Ozen S, Vierlinger K . EPIC-TABSAT: analysis tool for targeted bisulfite sequencing experiments and array-based methylation studies. Nucleic Acids Res. 2019; 47(W1):W166-W170. PMC: 6602470. DOI: 10.1093/nar/gkz398. View

15.

Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat S, Kim S . Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. Prostate. 2013; 74(2):210-6. DOI: 10.1002/pros.22742. View

16.

Wilkinson E, Raspin K, Malley R, Donovan S, Nott L, Holloway A . WNT5A is a putative epi-driver of prostate cancer metastasis to the bone. Cancer Med. 2024; 13(16):e70122. PMC: 11335815. DOI: 10.1002/cam4.70122. View

17.

Wang Q, Symes A, Kane C, Freeman A, Nariculam J, Munson P . A novel role for Wnt/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancer. PLoS One. 2010; 5(5):e10456. PMC: 2864254. DOI: 10.1371/journal.pone.0010456. View

18.

Syed Khaja A, Helczynski L, Edsjo A, Ehrnstrom R, Lindgren A, Ulmert D . Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome. PLoS One. 2011; 6(10):e26539. PMC: 3200334. DOI: 10.1371/journal.pone.0026539. View

19.

Chatterjee A, Rodger E, Eccles M . Epigenetic drivers of tumourigenesis and cancer metastasis. Semin Cancer Biol. 2017; 51:149-159. DOI: 10.1016/j.semcancer.2017.08.004. View

20.

Peters T, Buckley M, Statham A, Pidsley R, Samaras K, Lord R . De novo identification of differentially methylated regions in the human genome. Epigenetics Chromatin. 2015; 8:6. PMC: 4429355. DOI: 10.1186/1756-8935-8-6. View